Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

CB1 cannabinoid receptors mediate cognitive deficits and structural plasticity changes during nicotine withdrawal

  • Saravia Santos, Rocio, 1988-
  • Flores de los Heros, África, 1985-
  • Plaza-Zabala, Ainhoa, 1982-
  • Busquets Garcia, Arnau, 1985-
  • Pastor, Antonio
  • Torre Fornell, Rafael de la
  • Di Marzo, Vicenzo
  • Marsicano, Giovanni
  • Ozaita Mintegui, Andrés, 1969-
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
BACKGROUND: Tobacco withdrawal is associated with deficits in cognitive function, including attention, working memory, and episodic memory. Understanding the neurobiological mechanisms involved in these effects is crucial because cognitive deficits during nicotine withdrawal may predict relapse in humans. METHODS: We investigated in mice the role of CB1 cannabinoid receptors (CB1Rs) in memory impairment and spine density changes induced by nicotine withdrawal precipitated by the nicotinic antagonist mecamylamine. Drugs acting on the endocannabinoid system and genetically modified mice were used. RESULTS: Memory impairment during nicotine withdrawal was blocked by the CB1R antagonist rimonabant or the genetic deletion of CB1R in forebrain gamma-aminobutyric acidergic (GABAergic) neurons (GABA-CB1R). An increase of 2-arachidonoylglycerol (2-AG), but not anandamide, was observed during nicotine withdrawal. The selective inhibitor of 2-AG biosynthesis O7460 abolished cognitive deficits of nicotine abstinence, whereas the inhibitor of 2-AG enzymatic degradation JZL184 did not produce any effect in cognitive impairment. Moreover, memory impairment was prevented by the selective mammalian target of rapamycin inhibitor temsirolimus and the protein synthesis inhibitor anisomycin. Mature dendritic spines on CA1 pyramidal hippocampal neurons decreased 4 days after the precipitation of nicotine withdrawal, when the cognitive deficits were still present. Indeed, a correlation between memory performance and mature spine density was found. Interestingly, these structural plasticity alterations were normalized in GABA-CB1R conditional knockout mice and after subchronic treatment with rimonabant. CONCLUSIONS: These findings underline the interest of CB1R as a target to improve cognitive performance during early nicotine withdrawal. Cognitive deficits in early abstinence are associated with increased relapse risk., This work was supported by the Ministerio de Economía y Competitividad-MINECO (Grant No. SAF2014-59648-P to RM and Grant Nos. BFU2012-33500 and BFU2015-68568-P to AO), the Instituto de Salud Carlos III (Grant No. PI13/00042 to FB and RETICS-RTA, Grant No. RD12/0028/0023 to RM), the Generalitat de Catalunya-AGAUR (Grant No. 2014-SGR-1547 to RM), Plan Nacional sobre Drogas (Grant No. 2014I019 to FB), the European Commission (NeuroPain, Grant No. HEALTH-F2-2013-602891 to RM), FP7-PEOPLE-2013-IEF-623638, and French State/Agence Nationale de la Recherche/IdEx (Grant No. ANR-10-IDEX-03-02 to AB-G)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Specific hippocampal interneurons shape consolidation of recognition memory

  • Oliveira da Cruz, Jose F.
  • Busquets Garcia, Arnau, 1985-
  • Zhao, Zhe
  • Varilh, Marjorie
  • Lavanco, Gianluca
  • Robin, Laurie
  • Cannich, Astrid
  • Julio-Kalajzić, Francisca
  • Lesté-Lasserre, Thierry
  • Maître, Marlène
  • Drago, Filippo
  • Marsicano, Giovanni
  • Soria-Gómez, Edgar
A complex array of inhibitory interneurons tightly controls hippocampal activity, but how such diversity specifically affects memory processes is not well understood. We find that a small subclass of type 1 cannabinoid receptor (CB1R)-expressing hippocampal interneurons determines episodic-like memory consolidation by linking dopamine D1 receptor (D1R) signaling to GABAergic transmission. Mice lacking CB1Rs in D1-positive cells (D1-CB1-KO) display impairment in long-term, but not short-term, novel object recognition memory (NOR). Re-expression of CB1Rs in hippocampal D1R-positive cells rescues this NOR deficit. Learning induces an enhancement of in vivo hippocampal long-term potentiation (LTP), which is absent in mutant mice. CB1R-mediated NOR and the associated LTP facilitation involve local control of GABAergic inhibition in a D1-dependent manner. This study reveals that hippocampal CB1R-/D1R-expressing interneurons control NOR memory, identifying a mechanism linking the diversity of hippocampal interneurons to specific behavioral outcomes., We thank Delphine Gonzales, Nathalie Aubailly, and the personnel of the Animal Facilities of the NeuroCentre Magendie for mouse care. We thank the Biochemistry Platform of Bordeaux NeuroCampus and the members of Marsicano’s lab for useful discussions. This work was funded by INSERM; the European Research Council (Endofood ERC-2010-StG-260515, CannaPreg ERC-2014-PoC-640923, and MiCaBra ERC-2017-AdG-786467 to G.M.); Fondation pour la Recherche Medicale (FRM; DRM20101220445 to G.M. and DT20160435664 to J.F.O.d.C.); the Human Frontiers Science Program, Region Aquitaine, Agence Nationale de la Recherche (ANR; NeuroNutriSens ANR-13-BSV4-0006, ORUPS ANR-16-CE37-0010-01, and CaCoVi ANR-18-CE16-0001-02 to G.M.); BRAIN ANR-10-LABX-0043 (to G.M.); NIH/NIDA (1R21DA037678-01); the European Regional Development Fund; the European Union Horizon 2020 Research and Innovation Program (grant agreement 686009); French State/Agence Nationale de la Recherche/IdEx (ANR-10-IDEX-03-02), Eu-Fp7 (FP7-PEOPLE-2013-IEF-623638), and MINECO/AEI (RYC-2017-21776) (to A.B.-G.); FRM (ARF20140129235 to L.B.); and Ikerbasque (The Basque Foundation for Science) and MINECO (Ministerio de Economía y Competitividad) PGC2018-093990-A-I00 (MICIU/AEI/FEDER, UE) (to E.S.-G.).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Hippocampal protein kinase C signaling mediates the short-term memory impairment induced by delta9-tetrahydrocannabinol

  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Salgado Mendialdúa, Victòria
  • Galera López, Lorena, 1993-
  • Puighermanal Puigvert, Emma, 1983-
  • Martín García, Elena, 1975-
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Cannabis affects cognitive performance through the activation of the endocannabinoid system, and the molecular mechanisms involved in this process are poorly understood. Using the novel object-recognition memory test in mice, we found that the main psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), alters short-term object-recognition memory specifically involving protein kinase C (PKC)-dependent signaling. Indeed, the systemic or intra-hippocampal pre-treatment with the PKC inhibitors, prevented the short-term, but not the long-term, memory impairment induced by THC. In contrast, systemic pre-treatment with mammalian target of rapamycin complex 1 (mTORC1) inhibitors, known to block the amnesic-like effects of THC on long-term memory, did not modify such a short-term cognitive deficit. Immunoblot analysis revealed a transient increase in PKC signaling activity in the hippocampus after THC treatment. Thus, THC administration induced the phosphorylation of a specific Ser residue in the hydrophobic-motif at the C-terminal tail of several PKC isoforms. This significant immunoreactive band that paralleled cognitive performance did not match in size with the major PKC isoforms expressed in the hippocampus except for PKCθ. Moreover, THC transiently enhanced the phosphorylation of the postsynaptic calmodulin-binding protein neurogranin in a PKC dependent manner. These data demonstrate that THC alters short-term object-recognition memory through hippocampal PKC/neurogranin signaling., Predoctoral fellowship from the Spanish Ministry of Education (A. B-G. and E.P.). Partial support by FP7-PEOPLE-2013-IEF-623638 (A.B-G). Partial support by FRAXA Research Foundation (M.G-G.). Predoctoral fellowship by FPI (MINEICO/FEDER, EU) (V.S-M. and L.G-L). Research supported by BFU2015-68568P (A.O.), (MINECO/FEDER, UE); Redes temáticas de investigación cooperativa en salud (RETICS) del Instituto de Salud Carlos III (#RD16/0017/0020)-Red de trastornos adictivos (RTA) (R.M.); Generalitat de Catalunya, AGAUR (#2014-SGR-1547) (R.M.); ICREA (Institució Catalana de Recerca i Estudis Avançats) Acadèmia (R.M. and A.O.)
Addi. Archivo Digital para la Docencia y la Investigación
Publicación Artículo científico (JournalArticle)

Specific Hippocampal Interneurons Shape Consolidation of Recognition Memory

  • Oliveira da Cruz, Jose F.
  • Busquets García, Arnau
  • Zhao, Zhe
  • Varilh, Marjorie
  • Lavanco, Gianluca
  • Bellocchio, Luigi
  • Robin, Laurie
  • Cannich, Astrid
  • Julio Kalajzić, Francisca
  • Lesté Lasserre, Thierry
  • Maître, Marlène
  • Drago, Filippo
  • Marsicano, Giovanni
  • Soria Gómez, Edgar
A complex array of inhibitory interneurons tightly controls hippocampal activity, but how such diversity specifically affects memory processes is not well understood. We find that a small subclass of type 1 cannabinoid receptor (CB1R)-expressing hippocampal intemeurons determines episodic-like memory consolidation by linking dopamine D-1 receptor (D1R) signaling to GABAergic transmission. Mice lacking CB(1)Rs in D-1-positive cells (D-1-CB1-KO) display impairment in long-term, but not short-term, novel object recognition memory (NOR). Re-expression of CB(1)Rs in hippocampal D1R-positive cells rescues this NOR deficit. Learning induces an enhancement of in vivo hippocampal long-term potentiation (LTP), which is absent in mutant mice. CB1R-mediated NOR and the associated LTP facilitation involve local control of GABAergic inhibition in a D-1-dependent manner. This study reveals that hippocampal CB1R-/D1R-expressing interneurons control NOR memory, identifying a mechanism linking the diversity of hippocampal interneurons to specific behavioral outcomes., We thank Delphine Gonzales, Nathalie Aubailly, and the personnel of the Animal Facilities of the NeuroCentre Magendie for mouse care. We thank the Biochemistry Platform of Bordeaux NeuroCampus and the members of Marsicano's lab for useful discussions. This work was funded by INSERM; the European Research Council (Endofood ERC-2010-StG-260515, CannaPreg ERC-2014-PoC-640923, and MiCaBra ERC-2017-AdG-786467 to G.M.); Fondation pour la Recherche Medicale (FRM; DRM20101220445 to G.M. and DT20160435664 to J.F.O.d.C.); the Human Frontiers Science Program, Region Aquitaine, Agence Nationale de la Recherche (ANR; NeuroNutriSens ANR-13-BSV4-0006, ORUPS ANR-16-CE37-0010-01, and CaCoVi ANR-18-CE160001-02 to G.M.); BRAIN ANR-10-LABX-0043 (to G.M.); NIH/NIDA (1R21DA037678-01); the European Regional Development Fund; the European Union Horizon 2020 Research and Innovation Program (grant agreement 686009); French State/Agence Nationale de la Recherche/IdEx (ANR-10-IDEX-03-02), Eu-Fp7 (FP7-PEOPLE-2013-IEF-623638), and MINECO/AEI (RYC-2017-21776) (to A.B.-G.); FRM (ARF20140129235 to L.B.); and Ikerbasque (The Basque Foundation for Science) and MINECO (Ministerio de Economi ' a y Competitividad) PGC2018-093990-A-I00 (MICIU/AEI/FEDER, UE) (to E.S.-G.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glucose metabolism links astroglial mitochondria to cannabinoid effects

  • Jimenez-Blasco, Daniel
  • Busquets-Garcia, Arnau
  • Hebert-Chatelain, Etienne
  • Serrat, Roman
  • Vicente-Gutiérrez, Carlos
  • Ioannidou, Christina
  • Gómez-Sotres, Paula
  • López-Fabuel, Irene
  • Resch-Beusher, Monica
  • Resel, Eva
  • Arnouil, Dorian
  • Saraswat, Dave
  • Varilh, Marjorie
  • Cannich, Astrid
  • Julio-Kalajzic, Francisca
  • Bonilla-Del Río, Itziar
  • Almeida, Angeles
  • Puente, Nagore
  • Achicallende, Svein
  • López-Rodríguez, María L.
  • Jollé, Charlotte
  • Déglon, Nicole
  • Pellerin, Luc
  • Josephine, Charlene
  • Bonvento, Gilles
  • Panatier, Aude
  • Lutz, Beat
  • Piazza, Pier Vincenzo
  • Guzmán, Manuel
  • Bellocchio, Luigi
  • Bouzier-Sore, Anne-Karine
  • Grandes, Pedro
  • Bolaños, Juan P.
  • Marsicano, Giovanni
Astrocytes take up glucose from the bloodstream to provide energy to the brain, thereby allowing neuronal activity and behavioural responses1,2,3,4,5. By contrast, astrocytes are under neuronal control through specific neurotransmitter receptors5,6,7. However, whether the activation of astroglial receptors can directly regulate cellular glucose metabolism to eventually modulate behavioural responses is unclear. Here we show that activation of mouse astroglial type-1 cannabinoid receptors associated with mitochondrial membranes (mtCB1) hampers the metabolism of glucose and the production of lactate in the brain, resulting in altered neuronal functions and, in turn, impaired behavioural responses in social interaction assays. Specifically, activation of astroglial mtCB1 receptors reduces the phosphorylation of the mitochondrial complex I subunit NDUFS4, which decreases the stability and activity of complex I. This leads to a reduction in the generation of reactive oxygen species by astrocytes and affects the glycolytic production of lactate through the hypoxia-inducible factor 1 pathway, eventually resulting in neuronal redox stress and impairment of behavioural responses in social interaction assays. Genetic and pharmacological correction of each of these effects abolishes the effect of cannabinoid treatment on the observed behaviour. These findings suggest that mtCB1 receptor signalling can directly regulate astroglial glucose metabolism to fine-tune neuronal activity and behaviour in mice., This work was funded by: INSERM, the European Research Council (Endofood, ERC–2010–StG–260515 and CannaPreg, ERC-2014-PoC-640923, MiCaBra, ERC-2017-AdG-786467), Fondation pour la Recherche Medicale (FRM, DRM20101220445), the Human Frontiers Science Program, Region Nouvelle Aquitaine and Agence Nationale de la Recherche (ANR; NeuroNutriSens ANR-13-BSV4-0006, CaCoVi ANR 18-CE16-0001-02, MitObesity ANR 18-CE14-0029-01, ORUPS ANR-16-CE37-0010-01 and BRAIN ANR-10-LABX-0043) (to G.M.); NIH/NIDA (1R21DA037678-01), Spanish Ministry of Science, Innovation and Universities (MCINU/FEDER; grants SAF2016-78114-R and RED2018-102576-T), Instituto de Salud Carlos III (CB16/10/00282), an EU BATCure grant (666918), Junta de Castilla y León (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomedicina 2017 Fundación BBVA and Fundación Ramón Areces (to J.P.B.); Instituto de Salud Carlos III (PI18/00285; RD16/0019/0018), the European Regional Development Fund, the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement 686009), Junta de Castilla y León (IES007P17) and Fundación Ramón Areces to (A.A.); French State/ANR/IdEx (ANR-10-IDEX-03-02), Eu-Fp7 (FP7-PEOPLE-2013-IEF-623638) and Ramon y Cajal Investigator Program (RYC-2017-21776) (to A.B.-G.); FRM (SPF20121226369) (to R.S.); FRM (ARF20140129235) (to L.B.); Spanish Ministry of Science, Innovation and Universities (MCINU/FEDER; grants SAF2015-64945-R and RTI2018-095311-B-I00) (to M.G.); Canada Research Chair, Alzheimer Society of Canada—Brain Canada (17-09), Natural Sciences and Engineering Research Council (RGPIN-2015-05880), Canadian Breast Cancer Foundation (2015-317342), Canadian Health Research Institute (CIHR, 388808), New Brunswick Innovation Foundation, New Brunswick Health Research Foundation and Université de Moncton (to E.H.-C.); Basque Government (IT1230-19), Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III), European Regional Development Funds-European Union (ERDF-EU; RD16/0017/0012) and MINECO/FEDER, UE (SAF2015-65034-R) (to P.G.); University of the Basque Country PhD contract (PIF 16/251) (to S.A.); POP contract (BES-2016-076766, BES-C-2016-0051) (to I.B.-D.R.); French State/ANR (ANR-10-IDEX and TRAIL ANR-10-LABX-57); French-Swiss ANR-FNS (ANR-15- CE37-0012) (to A.-K.B.-S.); SFB/TRR 58 ‘Fear, anxiety, anxiety disorders’ (subproject A04); and CRC 1193 ‘Neurobiology of resilience’ (subproject B04) (to B.L.)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Hippocampal protein kinase C signaling mediates the short-term memory impairment induced by delta9-tetrahydrocannabinol

  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Salgado Mendialdúa, Victòria
  • Galera López, Lorena, 1993-
  • Puighermanal Puigvert, Emma, 1983-
  • Martín García, Elena, 1975-
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Cannabis affects cognitive performance through the activation of the endocannabinoid system, and the molecular mechanisms involved in this process are poorly understood. Using the novel object-recognition memory test in mice, we found that the main psychoactive component of cannabis, delta9-tetrahydrocannabinol (THC), alters short-term object-recognition memory specifically involving protein kinase C (PKC)-dependent signaling. Indeed, the systemic or intra-hippocampal pre-treatment with the PKC inhibitors, prevented the short-term, but not the long-term, memory impairment induced by THC. In contrast, systemic pre-treatment with mammalian target of rapamycin complex 1 (mTORC1) inhibitors, known to block the amnesic-like effects of THC on long-term memory, did not modify such a short-term cognitive deficit. Immunoblot analysis revealed a transient increase in PKC signaling activity in the hippocampus after THC treatment. Thus, THC administration induced the phosphorylation of a specific Ser residue in the hydrophobic-motif at the C-terminal tail of several PKC isoforms. This significant immunoreactive band that paralleled cognitive performance did not match in size with the major PKC isoforms expressed in the hippocampus except for PKCθ. Moreover, THC transiently enhanced the phosphorylation of the postsynaptic calmodulin-binding protein neurogranin in a PKC dependent manner. These data demonstrate that THC alters short-term object-recognition memory through hippocampal PKC/neurogranin signaling., Predoctoral fellowship from the Spanish Ministry of Education (A. B-G. and E.P.). Partial support by FP7-PEOPLE-2013-IEF-623638 (A.B-G). Partial support by FRAXA Research Foundation (M.G-G.). Predoctoral fellowship by FPI (MINEICO/FEDER, EU) (V.S-M. and L.G-L). Research supported by BFU2015-68568P (A.O.), (MINECO/FEDER, UE); Redes temáticas de investigación cooperativa en salud (RETICS) del Instituto de Salud Carlos III (#RD16/0017/0020)-Red de trastornos adictivos (RTA) (R.M.); Generalitat de Catalunya, AGAUR (#2014-SGR-1547) (R.M.); ICREA (Institució Catalana de Recerca i Estudis Avançats) Acadèmia (R.M. and A.O.)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Specific hippocampal interneurons shape consolidation of recognition memory

  • Oliveira da Cruz, Jose F.
  • Busquets Garcia, Arnau, 1985-
  • Zhao, Zhe
  • Varilh, Marjorie
  • Lavanco, Gianluca
  • Robin, Laurie
  • Cannich, Astrid
  • Julio-Kalajzić, Francisca
  • Lesté-Lasserre, Thierry
  • Maître, Marlène
  • Drago, Filippo
  • Marsicano, Giovanni
  • Soria-Gómez, Edgar
A complex array of inhibitory interneurons tightly controls hippocampal activity, but how such diversity specifically affects memory processes is not well understood. We find that a small subclass of type 1 cannabinoid receptor (CB1R)-expressing hippocampal interneurons determines episodic-like memory consolidation by linking dopamine D1 receptor (D1R) signaling to GABAergic transmission. Mice lacking CB1Rs in D1-positive cells (D1-CB1-KO) display impairment in long-term, but not short-term, novel object recognition memory (NOR). Re-expression of CB1Rs in hippocampal D1R-positive cells rescues this NOR deficit. Learning induces an enhancement of in vivo hippocampal long-term potentiation (LTP), which is absent in mutant mice. CB1R-mediated NOR and the associated LTP facilitation involve local control of GABAergic inhibition in a D1-dependent manner. This study reveals that hippocampal CB1R-/D1R-expressing interneurons control NOR memory, identifying a mechanism linking the diversity of hippocampal interneurons to specific behavioral outcomes., We thank Delphine Gonzales, Nathalie Aubailly, and the personnel of the Animal Facilities of the NeuroCentre Magendie for mouse care. We thank the Biochemistry Platform of Bordeaux NeuroCampus and the members of Marsicano’s lab for useful discussions. This work was funded by INSERM; the European Research Council (Endofood ERC-2010-StG-260515, CannaPreg ERC-2014-PoC-640923, and MiCaBra ERC-2017-AdG-786467 to G.M.); Fondation pour la Recherche Medicale (FRM; DRM20101220445 to G.M. and DT20160435664 to J.F.O.d.C.); the Human Frontiers Science Program, Region Aquitaine, Agence Nationale de la Recherche (ANR; NeuroNutriSens ANR-13-BSV4-0006, ORUPS ANR-16-CE37-0010-01, and CaCoVi ANR-18-CE16-0001-02 to G.M.); BRAIN ANR-10-LABX-0043 (to G.M.); NIH/NIDA (1R21DA037678-01); the European Regional Development Fund; the European Union Horizon 2020 Research and Innovation Program (grant agreement 686009); French State/Agence Nationale de la Recherche/IdEx (ANR-10-IDEX-03-02), Eu-Fp7 (FP7-PEOPLE-2013-IEF-623638), and MINECO/AEI (RYC-2017-21776) (to A.B.-G.); FRM (ARF20140129235 to L.B.); and Ikerbasque (The Basque Foundation for Science) and MINECO (Ministerio de Economía y Competitividad) PGC2018-093990-A-I00 (MICIU/AEI/FEDER, UE) (to E.S.-G.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

CB1 cannabinoid receptors mediate cognitive deficits and structural plasticity changes during nicotine withdrawal

  • Saravia Santos, Rocio, 1988-
  • Flores de los Heros, África, 1985-
  • Plaza-Zabala, Ainhoa, 1982-
  • Busquets Garcia, Arnau, 1985-
  • Pastor, Antonio
  • Torre Fornell, Rafael de la
  • Di Marzo, Vicenzo
  • Marsicano, Giovanni
  • Ozaita Mintegui, Andrés, 1969-
  • Maldonado, Rafael, 1961-
  • Berrendero Díaz, Fernando, 1971-
BACKGROUND: Tobacco withdrawal is associated with deficits in cognitive function, including attention, working memory, and episodic memory. Understanding the neurobiological mechanisms involved in these effects is crucial because cognitive deficits during nicotine withdrawal may predict relapse in humans. METHODS: We investigated in mice the role of CB1 cannabinoid receptors (CB1Rs) in memory impairment and spine density changes induced by nicotine withdrawal precipitated by the nicotinic antagonist mecamylamine. Drugs acting on the endocannabinoid system and genetically modified mice were used. RESULTS: Memory impairment during nicotine withdrawal was blocked by the CB1R antagonist rimonabant or the genetic deletion of CB1R in forebrain gamma-aminobutyric acidergic (GABAergic) neurons (GABA-CB1R). An increase of 2-arachidonoylglycerol (2-AG), but not anandamide, was observed during nicotine withdrawal. The selective inhibitor of 2-AG biosynthesis O7460 abolished cognitive deficits of nicotine abstinence, whereas the inhibitor of 2-AG enzymatic degradation JZL184 did not produce any effect in cognitive impairment. Moreover, memory impairment was prevented by the selective mammalian target of rapamycin inhibitor temsirolimus and the protein synthesis inhibitor anisomycin. Mature dendritic spines on CA1 pyramidal hippocampal neurons decreased 4 days after the precipitation of nicotine withdrawal, when the cognitive deficits were still present. Indeed, a correlation between memory performance and mature spine density was found. Interestingly, these structural plasticity alterations were normalized in GABA-CB1R conditional knockout mice and after subchronic treatment with rimonabant. CONCLUSIONS: These findings underline the interest of CB1R as a target to improve cognitive performance during early nicotine withdrawal. Cognitive deficits in early abstinence are associated with increased relapse risk., This work was supported by the Ministerio de Economía y Competitividad-MINECO (Grant No. SAF2014-59648-P to RM and Grant Nos. BFU2012-33500 and BFU2015-68568-P to AO), the Instituto de Salud Carlos III (Grant No. PI13/00042 to FB and RETICS-RTA, Grant No. RD12/0028/0023 to RM), the Generalitat de Catalunya-AGAUR (Grant No. 2014-SGR-1547 to RM), Plan Nacional sobre Drogas (Grant No. 2014I019 to FB), the European Commission (NeuroPain, Grant No. HEALTH-F2-2013-602891 to RM), FP7-PEOPLE-2013-IEF-623638, and French State/Agence Nationale de la Recherche/IdEx (Grant No. ANR-10-IDEX-03-02 to AB-G)